These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18030005)

  • 1. [Primary systemic chemotherapy for breast cancer].
    Takada M; Toi M
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
    Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
    Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
    Tokudome N; Ito Y
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):318-23. PubMed ID: 16531711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy of breast cancer.
    Garces CA; Cance WG
    Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
    Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible mechanisms behind taxane-anthracycline sequencing.
    Sahin I; Ararat E; Altundag K
    Lancet Oncol; 2010 Jun; 11(6):514-5. PubMed ID: 20522380
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current status of adjuvant chemotherapy for breast cancer].
    Takeuchi H; Okubo K; Fujiuchi N; Saeki T
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):736-41. PubMed ID: 16770090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
    Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
    Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two important determinants may play a role in the success of the FinHer Trial.
    Isik M; Dizdar O; Altundag K
    J Clin Oncol; 2010 Jul; 28(20):e334; author reply e335-6. PubMed ID: 20124158
    [No Abstract]   [Full Text] [Related]  

  • 13. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 15. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
    Davidson NE
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent perspectives second-line chemotherapy for breast cancer].
    Fujiuchi N; Ohokubo K; Saeki T; Sasaki Y
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):11-4. PubMed ID: 15675574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
    Tuxen MK; Cold S; Tange UB; Balslev E; Nielsen DL
    Acta Oncol; 2014 Oct; 53(10):1440-5. PubMed ID: 24991893
    [No Abstract]   [Full Text] [Related]  

  • 20. Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa.
    Altundag K; Altundag O; Baptista MZ; Atik MA
    Breast Cancer Res Treat; 2006 May; 97(2):221. PubMed ID: 16319972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.